Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 25 studies | 28% ± 9% | |
fibroblast | 20 studies | 22% ± 8% | |
pericyte | 19 studies | 23% ± 12% | |
macrophage | 14 studies | 20% ± 5% | |
type I pneumocyte | 11 studies | 28% ± 11% | |
classical monocyte | 11 studies | 22% ± 7% | |
smooth muscle cell | 10 studies | 22% ± 6% | |
epithelial cell | 10 studies | 31% ± 18% | |
capillary endothelial cell | 9 studies | 19% ± 4% | |
glutamatergic neuron | 9 studies | 35% ± 19% | |
monocyte | 8 studies | 19% ± 4% | |
non-classical monocyte | 8 studies | 22% ± 9% | |
endothelial cell of artery | 8 studies | 24% ± 5% | |
ciliated cell | 8 studies | 32% ± 9% | |
oligodendrocyte | 8 studies | 26% ± 8% | |
plasmacytoid dendritic cell | 8 studies | 22% ± 8% | |
basal cell | 7 studies | 27% ± 13% | |
vein endothelial cell | 7 studies | 19% ± 4% | |
natural killer cell | 6 studies | 18% ± 1% | |
endothelial cell of lymphatic vessel | 6 studies | 24% ± 7% | |
GABAergic neuron | 6 studies | 36% ± 17% | |
oligodendrocyte precursor cell | 6 studies | 26% ± 12% | |
endothelial cell of vascular tree | 6 studies | 22% ± 6% | |
connective tissue cell | 6 studies | 22% ± 8% | |
alveolar macrophage | 5 studies | 23% ± 4% | |
secretory cell | 5 studies | 30% ± 11% | |
astrocyte | 5 studies | 25% ± 3% | |
type II pneumocyte | 4 studies | 32% ± 11% | |
neuron | 4 studies | 41% ± 5% | |
CD16-positive, CD56-dim natural killer cell, human | 4 studies | 18% ± 2% | |
myofibroblast cell | 4 studies | 20% ± 5% | |
goblet cell | 4 studies | 22% ± 4% | |
interneuron | 4 studies | 39% ± 22% | |
microglial cell | 4 studies | 22% ± 7% | |
squamous epithelial cell | 3 studies | 45% ± 18% | |
pancreatic A cell | 3 studies | 40% ± 17% | |
type B pancreatic cell | 3 studies | 47% ± 25% | |
conventional dendritic cell | 3 studies | 26% ± 6% | |
glomerular endothelial cell | 3 studies | 31% ± 2% | |
myeloid cell | 3 studies | 28% ± 8% | |
retinal cone cell | 3 studies | 36% ± 7% | |
muscle cell | 3 studies | 25% ± 6% | |
dendritic cell | 3 studies | 37% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 8606.64 | 1445 / 1445 | 100% | 110.04 | 183 / 183 |
lung | 100% | 11959.42 | 578 / 578 | 100% | 140.94 | 1154 / 1155 |
brain | 100% | 11304.98 | 2640 / 2642 | 100% | 183.99 | 704 / 705 |
breast | 100% | 8880.10 | 459 / 459 | 100% | 132.15 | 1115 / 1118 |
pancreas | 100% | 7627.49 | 328 / 328 | 99% | 102.08 | 177 / 178 |
prostate | 100% | 6691.69 | 244 / 245 | 100% | 120.14 | 501 / 502 |
bladder | 100% | 8939.57 | 21 / 21 | 99% | 94.82 | 500 / 504 |
thymus | 100% | 9617.99 | 653 / 653 | 99% | 156.71 | 600 / 605 |
uterus | 100% | 9228.92 | 170 / 170 | 99% | 100.37 | 454 / 459 |
kidney | 100% | 6071.21 | 89 / 89 | 98% | 120.21 | 886 / 901 |
intestine | 100% | 8891.71 | 966 / 966 | 98% | 83.02 | 517 / 527 |
stomach | 100% | 7386.11 | 359 / 359 | 98% | 82.27 | 280 / 286 |
adrenal gland | 100% | 7602.27 | 258 / 258 | 97% | 118.14 | 224 / 230 |
ovary | 100% | 7115.08 | 180 / 180 | 97% | 62.50 | 416 / 430 |
liver | 100% | 5818.21 | 226 / 226 | 95% | 54.65 | 387 / 406 |
skin | 100% | 10399.13 | 1804 / 1809 | 93% | 91.51 | 437 / 472 |
blood vessel | 100% | 14945.41 | 1335 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 138.80 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 32.47 | 1 / 1 |
adipose | 100% | 9929.19 | 1203 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 6696.27 | 240 / 241 | 0% | 0 | 0 / 0 |
heart | 98% | 4860.04 | 846 / 861 | 0% | 0 | 0 / 0 |
muscle | 98% | 3707.10 | 785 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 60.92 | 28 / 29 |
peripheral blood | 77% | 5295.85 | 715 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 68% | 34.29 | 54 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0140331 | Biological process | aminophospholipid translocation |
GO_0006855 | Biological process | xenobiotic transmembrane transport |
GO_0010976 | Biological process | positive regulation of neuron projection development |
GO_0061092 | Biological process | positive regulation of phospholipid translocation |
GO_0070863 | Biological process | positive regulation of protein exit from endoplasmic reticulum |
GO_0045332 | Biological process | phospholipid translocation |
GO_0036010 | Biological process | protein localization to endosome |
GO_0015917 | Biological process | aminophospholipid transport |
GO_0016324 | Cellular component | apical plasma membrane |
GO_0031902 | Cellular component | late endosome membrane |
GO_0035579 | Cellular component | specific granule membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0031901 | Cellular component | early endosome membrane |
GO_0035577 | Cellular component | azurophil granule membrane |
GO_0005794 | Cellular component | Golgi apparatus |
GO_1990531 | Cellular component | phospholipid-translocating ATPase complex |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0030658 | Cellular component | transport vesicle membrane |
GO_0005198 | Molecular function | structural molecule activity |
GO_0005515 | Molecular function | protein binding |
GO_0015247 | Molecular function | aminophospholipid flippase activity |
Gene name | TMEM30A |
Protein name | Cell cycle control protein 50A (P4-ATPase flippase complex beta subunit TMEM30A) (Transmembrane protein 30A) Transmembrane protein 30A Cell cycle control protein |
Synonyms | CDC50A C6orf67 |
Description | FUNCTION: Accessory component of a P4-ATPase flippase complex which catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids from the outer to the inner leaflet of various membranes and ensures the maintenance of asymmetric distribution of phospholipids. Phospholipid translocation seems also to be implicated in vesicle formation and in uptake of lipid signaling molecules. The beta subunit may assist in binding of the phospholipid substrate. Required for the proper folding, assembly and ER to Golgi exit of the ATP8A2:TMEM30A flippase complex. ATP8A2:TMEM30A may be involved in regulation of neurite outgrowth, and, reconstituted to liposomes, predomiminantly transports phosphatidylserine (PS) and to a lesser extent phosphatidylethanolamine (PE). The ATP8A1:TMEM30A flippase complex seems to play a role in regulation of cell migration probably involving flippase-mediated translocation of phosphatidylethanolamine (PE) at the plasma membrane. Required for the formation of the ATP8A2, ATP8B1 and ATP8B2 P-type ATPAse intermediate phosphoenzymes. Involved in uptake of platelet-activating factor (PAF), synthetic drug alkylphospholipid edelfosine, and, probably in association with ATP8B1, of perifosine. Also mediates the export of alpha subunits ATP8A1, ATP8B1, ATP8B2, ATP8B4, ATP10A, ATP10B, ATP10D, ATP11A, ATP11B and ATP11C from the ER to other membrane localizations. . |
Accessions | A0A669KBF5 ENST00000674104.1 ENST00000674038.1 ENST00000475111.6 [Q9NV96-2] Q9NV96 ENST00000673730.1 ENST00000518161.1 ENST00000370050.9 [Q9NV96-3] ENST00000230461.11 [Q9NV96-1] A0A669KB92 ENST00000673989.1 ENST00000674151.1 [Q9NV96-3] A0A669KBE6 A0A669KBA0 E5RG19 |